Alpha Tau Medical Ltd. (DRTS)
| Market Cap | 843.15M +205.4% |
| Revenue (ttm) | n/a |
| Net Income | -56.88M |
| EPS | -0.67 |
| Shares Out | 90.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,390,932 |
| Open | 10.27 |
| Previous Close | 10.29 |
| Day's Range | 9.13 - 10.29 |
| 52-Week Range | 2.81 - 11.62 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 14.20 (+51.87%) |
| Earnings Date | May 18, 2026 |
About DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for DRTS stock is "Buy." The 12-month stock price target is $14.2, which is an increase of 51.87% from the latest price.
News
Alpha Tau price target raised to $17 from $15 at Barclays
Barclays raised the firm’s price target on Alpha Tau (DRTS) to $17 from $15 and keeps an Overweight rating on the shares. The company’s Tolmar commercialization deal provides revenue “optionality,”…
Alpha Tau, Tolmar announce strategic collaboration agreement
Alpha Tau (DRTS) and Tolmar announced a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer in the United States. Through the collaboration, ...
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
- Joint partnership leverages Alpha Tau's highly potent, localized alpha-radiation technology and Tolmar's commercial leadership to transform the U.S. uro-oncology landscape - Collaboration elevates ...
Alpha Tau reports positive survival data from pancreatic cancer study
Alpha Tau (DRTS) announced positive overall survival and safety results from a pooled analysis of three prospective Phase 1/2 clinical studies evaluating its Alpha DaRT therapy in patients with locall...
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of thre...
Alpha Tau Medical Transcript: Lytham Partners Spring 2026 Investor Conference
Major clinical trials in skin, pancreatic, and brain cancers are advancing, with key data expected by year-end. Combination studies show promising immune responses, and regulatory progress continues in the U.S., Israel, and Japan. $80M in cash supports milestones through 2026.
Alpha Tau initiated with an Overweight at Barclays
Barclays initiated coverage of Alpha Tau (DRTS) with an Overweight rating and $15 price target Alpha Tau is a biomedical company developing its Alpha DaRT radiotherapeutic implant for the treatment…
Alpha Tau price target raised to $8 from $5 at Piper Sandler
Piper Sandler raised the firm’s price target on Alpha Tau (DRTS) to $8 from $5 and keeps a Neutral rating on the shares after the company reported Q1 results, including…
Alpha Tau reports Q1 EPS (12c), consensus (12c)
“The first quarter of 2026 has been a truly defining period for Alpha Tau (DRTS), reflecting the convergence of two powerful dynamics that have been years in the making: the…
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of pat...
Alpha Tau Medical Earnings release: Q1 2026
Alpha Tau Medical released its Q1 2026 earnings on May 18, 2026, summarizing the period's financial results.
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, to...
Alpha Tau Medical Slides: Investor presentation
Alpha Tau Medical has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
Alpha Tau price target raised to $14 from $12 at Ladenburg
Ladenburg raised the firm’s price target on Alpha Tau (DRTS) to $14 from $12 and keeps a Buy rating on the shares after the company announced interim results from the…
Alpha Tau price target raised to $15 from $12 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Alpha Tau (DRTS) to $15 from $12 and keeps a Buy rating on the shares. The firm added potential sales of Alpha…
Alpha Tau Medical Transcript: Study result
Alpha DaRT demonstrated strong safety and efficacy in the first three recurrent GBM patients, with two complete responses and one significant tumor reduction. Adverse events were manageable, and the approach enables precise, localized treatment with potential for re-treatment and broad applicability.
Alpha Tau Medical Press release: Study result
Alpha Tau Medical issued a press release on May 11, 2026, disclosing material business information to investors.
Alpha Tau Medical Slides: Study result
Alpha Tau Medical has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Alpha Tau announces interim data from REGAIN trial
Alpha Tau (DRTS) announced interim data from its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma, also known as the REGAIN trial. In accordance with the FDA’s request…
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since ...
Alpha Tau completes enrollment in ReSTART trial
Alpha Tau (DRTS) announced the completion of enrollment in its ReSTART pivotal trial, a U.S. multicenter study evaluating the efficacy and safety of intratumoral Alpha DaRT for the treatment of…
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
JERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® to...
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
- First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA ...
Alpha Tau treats first patient with Alpha DaRT in Italy
Alpha Tau (DRTS) announced the treatment of the first patient in Italy in its feasibility and safety study of intratumoral diffusing alpha-emitter radiation for locally advanced pancreatic cancer. The...
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas Institute
First patient ever treated with Alpha DaRT for pancreatic cancer in Italy, under a clinical study conducted at the world-renowned Pancreas Institute of the University of Verona The study is the first ...